RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer in the Phase 3 MARIPOSA study

Submitted by Anonymous on

This is a paid press release. Contact the press release distributor directly with any inquiries. RYBREVANT® (amivantamab-vmjw) plus LAZCLUZE® (lazertinib) delivers statistically significant and clinically meaningful improvement in overall survival benefit for Asian patients with EGFR-mutated non-small cell lung cancer...

Design, synthesis, and insilico evaluation of 2-aminothiazole derivatives as potential mTOR and EGFR inhibitors

Submitted by Anonymous on

Abstract A series of 14 novel 2-aminothiazole (1a-1 g, 2a-2 g) derivatives were synthesized effectively and in silico evaluation was performed to find lead candidates as potential inhibitors targeting breast cancer receptors. One-pot three-component synthesis was carried out using different...

RBM8A confers oxaliplatin resistance in gastric cancer by maintaining EGFR mRNA stability

Submitted by Anonymous on

RNA-binding proteins (RBPs) critically regulate post-transcriptional gene expression, yet their roles in chemotherapy resistance remain underexplored. Here, through a targeted siRNA screen of 40 RBM family members, we identified RNA-binding motif protein 8 A (RBM8A) as central orchestrator of oxaliplatin-induced DNA...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia...

Submitted by Anonymous on

SOUTH SAN FRANCISCO, Calif. and SAN DIEGO, Dec. 05, 2025 (GLOBE NEWSWIRE) -- ORIC Pharmaceuticals, Inc. (Nasdaq: ORIC), a clinical stage oncology company focused on developing treatments that address mechanisms of therapeutic resistance, announced data from a Phase 1b trial...

ORIC® Pharmaceuticals Presents Potential Best-in-Class Profile for Enozertinib with Robust Systemic and CNS Activity in 1L and 2L NSCLC Patients with EGFR Exon 20 Mutations at the ESMO Asia Congress 2025

Submitted by Anonymous on

Highly differentiated 1L preliminary systemic activity of 67% ORR and 100% intracranial ORR (by BICR-RANO), including in patients with active brain metastases 45% ORR in 2L patients exceeds competitor benchmarks Competitive safety profile, with no significant off-target toxicity and manageable...

The impact of initiating SGLT2 inhibitors on eGFR: a pilot study at a secondary hospital in Malaysia

Submitted by Anonymous on

AbstractObjective The purpose of this study was to evaluate the effect of sodium–glucose cotransporter 2 inhibitors on estimated glomerular filtration rate and serum creatinine among patients with type 2 diabetes mellitus and chronic kidney disease receiving treatment in a secondary...

Triazole–Schiff Base Hybrids as Potential Dual Inhibitors of Bcl-2 and EGFR: Synthesis, Characterization, and Computational Insights

Submitted by Anonymous on

Abstract Cancer remains a major global health challenge, requiring the development of novel therapeutic agents with high efficacy and minimal side effects. In this study, we designed and synthesised a series of hybrid molecules incorporating triazoles, Schiff bases and substituted...

Subscribe to Newsfeed